ObsEva (NASDAQ:OBSV) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of ObsEva (NASDAQ:OBSV) in a research report released on Saturday. The brokerage issued a hold rating on the stock.

ObsEva Stock Performance

The stock has a market capitalization of $7.94 million, a PE ratio of -0.11 and a beta of 0.68. ObsEva has a 12 month low of $0.08 and a 12 month high of $2.14.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.